What is InformedDNA?
InformedDNA operates as the preeminent authority on the appropriate application of genetic testing, maintaining the largest independent staff of board-certified genetics specialists in the United States. The company serves a diverse ecosystem of stakeholders, including health plans, health systems, pharmaceutical entities, and clinicians. Its core service architecture encompasses clinical genetic counseling, rigorous testing utilization management, and payment integrity solutions. By providing expert genetics support for clinical trials, InformedDNA ensures that stakeholders navigate the complexities of genomic medicine with precision, thereby reducing unnecessary costs while optimizing patient care pathways through evidence-based decision support.
How much funding has InformedDNA raised?
InformedDNA has raised a total of $22.2M across 4 funding rounds:
Private Equity
$7.7M
Unspecified
$3M
Private Equity
$5M
Private Equity
$6.5M
Private Equity (2013): $7.7M, investors not publicly disclosed
Unspecified (2013): $3M led by MPM Capital
Private Equity (2014): $5M supported by Zaffre Investments, LLC.
Private Equity (2016): $6.5M, investors not publicly disclosed
Key Investors in InformedDNA
MPM Capital
MPM BioImpact manages early-stage venture funds and private/public impact funds, focusing on converting scientific innovation into viable therapeutics for patients.
Zaffre Investments, LLC.
A subsidiary of Blue Cross Blue Shield of Massachusetts, this firm invests in healthcare technologies and services that improve delivery models and patient outcomes.
What's next for InformedDNA?
With a robust foundation established through successive rounds of private equity and strategic investment, InformedDNA is well-positioned to scale its digital health offerings. The company's roadmap likely involves deepening its integration with health systems to automate genetic testing workflows and expanding its footprint in the pharmaceutical sector to support precision medicine initiatives. As the demand for genomic literacy grows, InformedDNA is expected to leverage its proprietary expertise to influence policy and standard-of-care protocols, further cementing its role as an essential intermediary in the rapidly evolving healthcare technology market.
See full InformedDNA company page
